指南与共识系统性红斑狼疮

EULAR 2025 系统性红斑狼疮肾脏受累管理建议更新

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.
指南 / 共识 · Ann Rheum Dis · 2025-10-16

该建议由国际专家组按EULAR标准操作流程制定,系统检索2019年1月至2024年3月文献并经改良Delphi法达成共识,形成4条总体原则和13条建议,涵盖肾活检、治疗目标、免疫调节与非免疫治疗、生育计划及肾衰竭管理。

要点

  • 共识形成4条总体原则和13条建议,并评估可行性与临床影响。
  • 建议涉及肾活检诊断、治疗目标与里程碑及免疫调节方案。
  • 免疫调节涵盖抗疟药、糖皮质激素、免疫抑制剂与生物制剂。

核心结论

  • 更新版EULAR建议基于证据与专家共识,按严重程度调整,并考虑长期疗效、安全性、费用及药物本地可及性。

研究设计与样本

  • 组建国际专家组,遵循EULAR标准操作流程,系统检索2019年1月至2024年3月文献,采用改良Delphi法形成问题、征集专家意见并达成共识。

主要发现

  • 专家组就4条总体原则和13条建议达成一致,并评估其可行性与对临床照护的影响。
  • 建议内容涉及肾活检用于诊断、治疗目标与治疗里程碑。
  • 免疫调节治疗涉及抗疟药、糖皮质激素、免疫抑制剂(霉酚酸酯、环磷酰胺、钙调神经磷酸酶抑制剂)和生物制剂(贝利尤单抗、奥妥珠单抗、利妥昔单抗)。
  • 非免疫治疗涉及肾脏保护、疫苗接种、心血管与骨骼保护;另涉及生育计划和肾衰竭管理。
  • 就单药或早期联合免疫治疗、糖皮质激素减量与停用、免疫治疗疗程及难治性疾病治疗提供指导。

关键数值与推荐

  • 形成4条总体原则和13条建议。
  • 系统文献检索时段为2019年1月至2024年3月。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to update the 2019 European Alliance of Associations for Rheumatology (EULAR)/ European Renal Association/European Dialysis Transplantation Association (ERA-EDTA) recommendations for the management of systemic lupus erythematosus (SLE) with kidney involvement, taking into consideration emerging evidence and recent developments in the field. METHODS: We recruited an international Task Force of experts and followed the EULAR standard operating procedures. We performed systematic literature research (period January 2019 to March 2024), followed by the modified Delphi method, to form questions, elicit expert opinions, and reach consensus. The new evidence was examined, taking into consideration previous updates. RESULTS: The Task Force agreed on 4 overarching principles and 13 recommendations, which were also evaluated for their feasibility and impact on clinical care. These concern the use of kidney biopsy for diagnosis; targets of therapy and treatment milestones; immunomodulatory therapy with antimalarials, glucocorticoids, immunosuppressives (mycophenolate, cyclophosphamide, and calcineurin inhibitors), and biologics (belimumab, obinutuzumab, and rituximab); nonimmune therapy (kidney protection, vaccinations, cardiovascular, and bone protection); family planning; and management of kidney failure. Guidance on single-agent or early combination immune therapy, glucocorticoid tapering and withdrawal, duration of immune therapy, and treatment of refractory disease is provided. CONCLUSIONS: The updated EULAR recommendations provide evidence- and expert-based consensus on the management of SLE with kidney involvement, adjusted for severity, and taking into consideration long-term efficacy, safety, cost, and local availability of drugs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2025. PMID: 41107121. doi:10.1016/j.ard.2025.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。